SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (92)7/19/2001 1:15:31 PM
From: sam  Respond to of 897
 
Thanks.



To: scaram(o)uche who wrote (92)7/25/2001 2:43:03 PM
From: sam  Read Replies (1) | Respond to of 897
 
Is Avalon the real deal? Well, looks like we'll be getting a fair opportunity to test Avalon's research "skills" tomorrow when flu-mist comes before the FDA. The street is betting with AVIR, at least today. Buying or short covering? No clue here. Should be interesting, in any event.



To: scaram(o)uche who wrote (92)10/8/2001 12:35:10 PM
From: tuck  Read Replies (2) | Respond to of 897
 
Rick,

I've only loosely followed GLIA recently. I take it you've noted LCBM's FDA approaval of a product that apparently competes. Any opinion on how competitive it is?

No recent insider moves, but the chart looks toppy:

siliconinvestor.com

At $150 million, LCBM has almost 5x the market cap of GLIA, but despite GLIA's problems, it is behind in the marketplace now that GLIA is getting ready to restart manufacturing of ADCON, IMO.

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News